C97 Stock Overview
A molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Co-Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.03 |
| 52 Week High | US$1.60 |
| 52 Week Low | US$0.85 |
| Beta | -0.86 |
| 11 Month Change | -18.90% |
| 3 Month Change | -10.43% |
| 1 Year Change | 4.46% |
| 33 Year Change | -86.79% |
| 5 Year Change | 4.01% |
| Change since IPO | -5.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| C97 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -9.6% | 12.7% | 4.5% |
| 1Y | 4.5% | 9.1% | 13.5% |
Return vs Industry: C97 underperformed the German Medical Equipment industry which returned 9.1% over the past year.
Return vs Market: C97 underperformed the German Market which returned 13.4% over the past year.
Price Volatility
| C97 volatility | |
|---|---|
| C97 Average Weekly Movement | 13.4% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C97's share price has been volatile over the past 3 months.
Volatility Over Time: C97's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 155 | Dwight Egan | www.codiagnostics.com |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.
Co-Diagnostics, Inc. Fundamentals Summary
| C97 fundamental statistics | |
|---|---|
| Market cap | €35.15m |
| Earnings (TTM) | -€33.65m |
| Revenue (TTM) | €8.18m |
4.3x
P/S Ratio-1.0x
P/E RatioIs C97 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C97 income statement (TTM) | |
|---|---|
| Revenue | US$9.14m |
| Cost of Revenue | US$3.67m |
| Gross Profit | US$5.47m |
| Other Expenses | US$43.04m |
| Earnings | -US$37.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.18 |
| Gross Margin | 59.83% |
| Net Profit Margin | -411.19% |
| Debt/Equity Ratio | 0% |
How did C97 perform over the long term?
See historical performance and comparison